A controversial clotting drug pulled from sale in Canada and abroad several years ago is being allowed back on the Canadian market. Health Canada announced Wednesday it is letting Bayer Inc. resume sales of aprotinin, marketed under the brand name Trasylol. The company agreed to suspend sales of the drug in the fall of 2007 after a Canadian-led clinical trial comparing it to two other clotting drugs was stopped early by its independent safety monitoring board. All clinical trials have a board of uninvolved experts who review the data on an ongoing basis to ensure patients aren’t being harmed.
